None listed
Conditions
Interventions
None listed
Sponsors
Dr Nandini Sharma
Eligibility
Inclusion criteria
Inclusion criteria: Individuals currently residing and likely to stay till the end of one year in the study area. Consented to participate in both sections of the study (Sero - Prevalence and AFI Surveillance) and follow all procedures.
Exclusion criteria
Exclusion criteria: Ongoing fever episodes or history of AFI on or before enrolment for the cohort
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Age specific attack rate The proportion of individuals per age strata who show Sero conversion between two rounds 2 Age-specific cumulative incidence of asymptomatic infections The proportion of individuals per age strata who show seroconversion over 1 year but do not report any symptoms suggestive of the infection during AFI/ILI surveillance 3 Age-specific cumulative incidence of symptomatic events The proportion of individuals reported / diagnosed with disease under surveillance 4 Age Specific sero prevalence and sero incidence of neutralizing antibodies The proportion of individuals showing presence of neutralizing antibodies at baseline and at end line.Timepoint: at end of one year | — |
Secondary
| Measure | Time frame |
|---|---|
| Symptomatic proportion of cases (asymptomatic fraction) The proportion of individuals who show symptoms or signs of Dengue / Chikungunya infection 6 Prevalence and incidence of Circulating serotypes The proportion of symptomatic and asymptomatic cases with type of circulating serotype. 7 Population groups most at risk The identification of groups who are most vulnerable to Dengue ad Chikungunya infection (e.g. age groups, gender, occupation) 8 Validity of IgG ELISA The sensitivity and specificity of IgG ELISA will be calculated against PRNT (Neutralizing antibodies).Timepoint: at end of one year | — |
Countries
India
Contacts
Public ContactDr Heena Lalwani
Maulana Azad Medical College
Outcome results
None listed